Castration-resistant prostate cancer (CRPC) is still a lethal disease even after the development of a new generation of hormonal drugs or chemotherapy, and thus the development of novel therapeutic ...

Data from 2 studies, LIGHTHOUSE and SPOTLIGHT, have shown the benefit of flotufolastat F 18 injection as a radiohybrid PSMA-targeted PET imaging agent in prostate cancer. The agent has now been added ...

Enzyme ablation of the hyperplastic prostate may be an ideal method of management of BPH. However, the unsatisfactory ablation affects in vivo contrast with successful in vitro results limiting the ...

MONROE TOWNSHIP, NJ, & OXFORD, England--(BUSINESS WIRE)--Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, ...

Prostatitis and BPH (benign prostatic hyperplasia) are distinct conditions affecting the prostate gland. Although both conditions involve the prostate, they have different causes, symptoms, treatments ...

Prostatitis is inflammation of the prostate, which can be acute or chronic. Chronic prostatitis can be triggered by a bacterial infection, but in many cases, the cause is unknown. Share on Pinterest ...

The objective of androgen deprivation therapy (ADT) in men with prostate cancer is to maintain very low levels of testosterone so that the hormone does not promote tumor growth. But a new analysis ...

A detailed analysis of von Hippel Lindau (VHL) mutations in sporadic clear cell renal carcinoma (ccRCC), VHL syndrome, and Chuvash polycythaemia. Background: GLIPR1/RTVP-1 is up-regulated by p53 in ...

FDA approves Jevtana injection for prostate cancer Sanofi-aventis announced that the FDA has approved Jevtana (cabazitaxel injection) in combination with prednisone for the treatment of patients with ...